Prescription Drug Recall: ABILIFY Tablets Due to Cross Contamination
ABILIFY (aripiprazole) 15 mg tablets from lot AMS00223A are being recalled due to cross contamination with other products. The recall affects packages distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. Per the severity rubric, FDA Class III recalls are typically rated 1 or 2. The cross-contamination is characterized as low-risk contamination without evidence of actual harm, supporting a Moderate (score 2) rating.
Plain-English summary
Otsuka Pharmaceutical Co., Ltd. is recalling ABILIFY (aripiprazole) 15 mg tablets in 30-count bottles due to cross contamination with other products. The affected lot is AMS00223A with an expiration date of July 31, 2025.
This recall applies to ABILIFY 15 mg tablets distributed nationwide in the United States. Patients who have received this medication from the affected lot should contact their healthcare provider or pharmacist for guidance.
Further information about this recall and manufacturer contact details are available through the FDA's drug safety and availability website.
The recalled product
- Product
- ABILIFY (ARIPIPRAZOLE)
- Brand
- ABILIFY
- Manufacturer
- Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
- Category
- Drug
- Hazard
- cross-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # AMS00223A
- Exp 07/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ABILIFY
- ModeratePrescription medication Abilify recalled for cross contamination with other products
FDA (Drugs) · 2024-05-01
- ModeratePrescription drug Abilify 30mg tablets recalled for cross-product contamination
FDA (Drugs) · 2024-05-01
- ModeratePrescription antipsychotic tablets Abilify recalled for cross-contamination with other products
FDA (Drugs) · 2024-05-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27